Worldwide Acetaminophen Industry to 2031 - by Product, Sales Type, Route of Administration, Distribution Channel and Region

Company Logo

Dublin, May 30, 2022 (GLOBE NEWSWIRE) -- The "Acetaminophen Market" report has been added to ResearchAndMarkets.com's offering.

This report on the acetaminophen market offers a global industry analysis for 2016-2020 and an opportunity assessment for 2021-2031.

The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the acetaminophen market, growth prospects of the market are obtained with maximum precision.

The report features unique and salient factors that may make a huge impact on the development of the acetaminophen market during the forecast period.

It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.

The report provides detailed information about the current and future growth prospects of acetaminophen market in the most comprehensive way for better understanding of readers.

Key Topics Covered:

1. Executive Summary

2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation/Development Trends

4. Key Success Factors
4.1. Key Strategies Adopted By Manufactures
4.2. Regulatory Scenario
4.3. Pipeline Analysis
4.4. Disease Epidemiology

5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Per Capita Healthcare Expenditure Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Average Annual Spending on Pain Management Drugs
5.2.2. Average Healthcare Expenditure
5.2.3. Increasing Prevalence of Chronic and Acute Diseases
5.2.4. Growing Number of Patients undergoing Surgical Interventions
5.2.5. Rising Number of Population Suffering from End-stage Diseases
5.2.6. Per Capita Pharmaceutical Expenditure
5.2.7. Awareness for Pain Management Drugs
5.2.8. Favourable Reimbursement Policies
5.2.9. Regulatory Control over Prescription
5.2.10. Popularity of Generic Products
5.2.11. Patent Expiration of Novel Pain Management Drugs (Opioids)
5.2.12. Introduction of Novel Abuse-deterrent Pain Management Drugs
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis
6.1. Current COVID19 Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.4.1.1. Revenue By Product
6.4.1.2. Revenue By Sales Type
6.4.1.3. Revenue By Route Of Administration
6.4.1.4. Revenue By Distribution Channel
6.4.1.5. Revenue By Country
6.5. 2020 Market Scenario

7. Global Acetaminophen Market Demand (in Value or Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis

8. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, By Product
8.1. Introduction/Key Findings
8.2. Historical Market Size (US$ Mn) Trend Analysis By Product, 2016-2020
8.3. Current and Future Market Size (US$ Mn) Trend Analysis and Forecast By Product, 2021-2031
8.3.1. Opioids Acetaminophen
8.3.2. Anaesthetics Acetaminophen
8.3.3. Other Acetaminophen
8.4. Market Attractiveness Analysis By Product

9. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, By Sales Type
9.1. Introduction/Key Findings
9.2. Historical Market Size (US$ Mn) Trend Analysis By Sales Type, 2016-2020
9.3. Current and Future Market Size (US$ Mn) Trend Analysis and Forecast By Sales Type, 2021-2031
9.3.1. Prescription (Rx)
9.3.2. Over the counter (OTC)
9.4. Market Attractiveness Analysis By Sales Type

10. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, By Route Of Administration
10.1. Introduction/Key Findings
10.2. Historical Market Size (US$ Mn) Trend Analysis By Route Of Administration, 2016-2020
10.3. Current and Future Market Size (US$ Mn) Trend Analysis and Forecast By Route Of Administration, 2021-2031
10.3.1. Oral
10.3.2. lnjectable
10.3.3. others
10.4. Market Attractiveness Analysis By Route Of Administration

11. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, by Distribution Channel
11.1. Introduction/Key Findings
11.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2016-2020
11.3. Current and Future Market Size (US$ Mn) Trend Analysis and Forecast By Distribution Channel, 2021-2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Drug Stores
11.3.4. E-commerce
11.3.5. Others
11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, by Region
12.1. Introduction/Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East & Africa
12.4. Market Attractiveness Analysis By Region

13. North America Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

14. Latin America Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

15. Europe Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

16. South Asia Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

17. East Asia Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

18. Oceania Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

19. Middle East and Africa Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

20. Country Level Analysis, Acetaminophen Market Forecast 2021-2031

21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Deep Dive
21.2.1. Pfizer Inc.
21.2.1.1. Overview
21.2.1.2. Services Portfolio
21.2.1.3. Profitability by Market Segments (Product/Channel/Region)
21.2.1.4. Sales Footprint
21.2.1.5. Strategy Overview
21.2.1.5.1. Marketing Strategy
21.2.1.5.2. Services Strategy
21.2.1.5.3. Channel Strategy
21.2.2. Sanofi
21.2.2.1. Overview
21.2.2.2. Services Portfolio
21.2.2.3. Profitability by Market Segments (Product/Channel/Region)
21.2.2.4. Sales Footprint
21.2.2.5. Strategy Overview
21.2.2.5.1. Marketing Strategy
21.2.2.5.2. Services Strategy
21.2.2.5.3. Channel Strategy
21.2.3. Janssen Pharmaceuticals.
21.2.3.1. Overview
21.2.3.2. Services Portfolio
21.2.3.3. Profitability by Market Segments (Product/Channel/Region)
21.2.3.4. Sales Footprint
21.2.3.5. Strategy Overview
21.2.3.5.1. Marketing Strategy
21.2.3.5.2. Services Strategy
21.2.3.5.3. Channel Strategy
21.2.4. Bayer AG
21.2.4.1. Overview
21.2.4.2. Services Portfolio
21.2.4.3. Profitability by Market Segments (Product/Channel/Region)
21.2.4.4. Sales Footprint
21.2.4.5. Strategy Overview
21.2.4.5.1. Marketing Strategy
21.2.4.5.2. Services Strategy
21.2.4.5.3. Channel Strategy
21.2.5. GlaxoSmithKline plc
21.2.5.1. Overview
21.2.5.2. Services Portfolio
21.2.5.3. Profitability by Market Segments (Product/Channel/Region)
21.2.5.4. Sales Footprint
21.2.5.5. Strategy Overview
21.2.5.5.1. Marketing Strategy
21.2.5.5.2. Services Strategy
21.2.5.5.3. Channel Strategy
21.2.6. Bristol-Myers Squibb and Company
21.2.6.1. Overview
21.2.6.2. Services Portfolio
21.2.6.3. Profitability by Market Segments (Product/Channel/Region)
21.2.6.4. Sales Footprint
21.2.6.5. Strategy Overview
21.2.6.5.1. Marketing Strategy
21.2.6.5.2. Services Strategy
21.2.6.5.3. Channel Strategy
21.2.7. Teva Pharmaceutical Industries Ltd
21.2.7.1. Overview
21.2.7.2. Services Portfolio
21.2.7.3. Profitability by Market Segments (Product/Channel/Region)
21.2.7.4. Sales Footprint
21.2.7.5. Strategy Overview
21.2.7.5.1. Marketing Strategy
21.2.7.5.2. Services Strategy
21.2.7.5.3. Channel Strategy
21.2.8. Cardinal Health Inc.
21.2.8.1. Overview
21.2.8.2. Services Portfolio
21.2.8.3. Profitability by Market Segments (Product/Channel/Region)
21.2.8.4. Sales Footprint
21.2.8.5. Strategy Overview
21.2.8.5.1. Marketing Strategy
21.2.8.5.2. Services Strategy
21.2.8.5.3. Channel Strategy
21.2.9. Perrigo Company.
21.2.9.1. Overview
21.2.9.2. Services Portfolio
21.2.9.3. Profitability by Market Segments (Product/Channel/Region)
21.2.9.4. Sales Footprint
21.2.9.5. Strategy Overview
21.2.9.5.1. Marketing Strategy
21.2.9.5.2. Services Strategy
21.2.9.5.3. Channel Strategy
21.2.10. Novartis AG
21.2.10.1. Overview
21.2.10.2. Services Portfolio
21.2.10.3. Profitability by Market Segments (Product/Channel/Region)
21.2.10.4. Sales Footprint
21.2.10.5. Strategy Overview
21.2.10.5.1. Marketing Strategy
21.2.10.5.2. Services Strategy
21.2.10.5.3. Channel Strategy
21.2.11. Sun Pharmaceutical Industries Ltd
21.2.11.1. Overview
21.2.11.2. Services Portfolio
21.2.11.3. Profitability by Market Segments (Product/Channel/Region)
21.2.11.4. Sales Footprint
21.2.11.5. Strategy Overview
21.2.11.5.1. Marketing Strategy
21.2.11.5.2. Services Strategy
21.2.11.5.3. Channel Strategy
21.2.12. Abbott
21.2.12.1. Overview
21.2.12.2. Services Portfolio
21.2.12.3. Profitability by Market Segments (Product/Channel/Region)
21.2.12.4. Sales Footprint
21.2.12.5. Strategy Overview
21.2.12.5.1. Marketing Strategy
21.2.12.5.2. Services Strategy
21.2.12.5.3. Channel Strategy
21.2.13. Mallinckrodt Pharmaceuticals
21.2.13.1. Overview
21.2.13.2. Services Portfolio
21.2.13.3. Profitability by Market Segments (Product/Channel/Region)
21.2.13.4. Sales Footprint
21.2.13.5. Strategy Overview
21.2.13.5.1. Marketing Strategy
21.2.13.5.2. Services Strategy
21.2.13.5.3. Channel Strategy
21.2.14. Procter & Gamble Company
21.2.14.1. Overview
21.2.14.2. Services Portfolio
21.2.14.3. Profitability by Market Segments (Product/Channel/Region)
21.2.14.4. Sales Footprint
21.2.14.5. Strategy Overview
21.2.14.5.1. Marketing Strategy
21.2.14.5.2. Services Strategy
21.2.14.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/mgb94d

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900